Press Release: BB Biotech admitted to the Stoxx Europe 600

BB Biotech AG / BB Biotech admitted to the Stoxx Europe 600 . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Admission thanks to increased market capitalization

BB Biotech will be admitted to the Stoxx Europe 600 on December 22, 2014. This decision was made on November 25, 2014 in view of the increased free-float market capitalization and the investment company's higher liquidity. The market capitalization has risen significantly thanks to a strong performance and is currently over CHF 2.6 billion. BB Biotech's share price has gained 66% since the beginning of the year, while growth over the last 3 years amounts to more than 320% (in CHF, as at 27.11.2014). Daniel Koller, Head of the Management Team, says: "Our admission to the Stoxx Europe 600 is another milestone for BB Biotech and is testament to our ongoing success of the last few years."

The Stoxx Europe stock market index comprises 600 listed companies from 18 European countries. These include 200 large cap, 200 mid-cap and 200 small-cap stocks from various sectors such as banking, telecommunications, healthcare and technology. The composition of the index is reviewed four times a year. Prices on the Stoxx Europe 600 are listed daily between 9am and 5.30pm.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland

Tanja Chicherio, phone +41 44 267 67 00, tch@bellevue.ch

b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland

Thomas Egger, phone +41 79 423 22 28, teg@b-public.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.3 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

Press Release (PDF): http://hugin.info/130285/R/1875179/660756.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BB BIOTECH AG via Globenewswire

HUG#1875179

--- End of Message ---

BB BIOTECH AG

Vordergasse 3 Schaffhausen Switzerland

WKN: AONFN3;ISIN: CH0038389992;

(END) Dow Jones Newswires

   November 28, 2014 07:59 ET (12:59 GMT)- - 07 59 AM EST 11-28-14